Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study.

about

Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study.

Item

http://www.wikidata.org/entity/Q55689035

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Vinorelbine in BRAF V600E muta ...... entre phase II clinical study.

@en

Vinorelbine in BRAF V600E muta ...... entre phase II clinical study.

@nl

type

Item

label

Vinorelbine in BRAF V600E muta ...... entre phase II clinical study.

@en

Vinorelbine in BRAF V600E muta ...... entre phase II clinical study.

@nl

prefLabel

Vinorelbine in BRAF V600E muta ...... entre phase II clinical study.

@en

Vinorelbine in BRAF V600E muta ...... entre phase II clinical study.

@nl

P1476

Vinorelbine in BRAF V600E muta ...... entre phase II clinical study.

@en

P2093

Alfredo Falcone

http://www.w3.org/2001/XMLSchema#string

Carlotta Antoniotti

http://www.w3.org/2001/XMLSchema#string

Chiara Cremolini

http://www.w3.org/2001/XMLSchema#string

Daniele Rossini

http://www.w3.org/2001/XMLSchema#string

Federica Marmorino

http://www.w3.org/2001/XMLSchema#string

Gianluca Tomasello

http://www.w3.org/2001/XMLSchema#string

Marta Schirripa

http://www.w3.org/2001/XMLSchema#string

Michele Prisciandaro

http://www.w3.org/2001/XMLSchema#string

Roberto Moretto

http://www.w3.org/2001/XMLSchema#string

Stamatia Ziampiri

http://www.w3.org/2001/XMLSchema#string

P2860

Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients.

MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.

The consensus molecular subtypes of colorectal cancer

Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.

Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation.

Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer.

A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer.

Optimal two-stage designs for phase II clinical trials.

Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation.

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.

P304

e000241

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ESMOOPEN-2017-000241

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-08-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29209533

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

5703381

http://www.w3.org/2001/XMLSchema#string